COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

Search Results

One moment please while the data are loaded...

The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:

  • Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
  • Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
  • Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
View results
  • Organ: Pituitary Gland
  • Level of Evidence: Positive, Clear Evidence, Some Evidence
Displays results that match exactly with the given criteria.
Exact Match Publication No. CASRN Test Article Name Species Strain Sex Route Organ Level of Evidence Organ Site Call Tumor Type/Incidence Finding Type
Yes TR-235 17924-92-4 Zearalenone Mice B6C3F1 Female Dosed-Feed Pituitary Gland Positive Positive ADENOMA 3/46 2/43 13/42 Neoplastic Lesions
Yes TR-235 17924-92-4 Zearalenone Mice B6C3F1 Male Dosed-Feed Pituitary Gland Positive Positive ADENOMA 0/40 4/45 6/44 Neoplastic Lesions
Yes TR-332 149-30-4 2-Mercaptobenzothiazole Rats F344/N Female Gavage Pituitary Gland Some Evidence Some Evidence ADENOMA 15/49 24/50 25/50 Neoplastic Lesions
Yes TR-388 96-45-7 Ethylene thiourea (ETU) Mice B6C3F1 Male Dosed-Feed Pituitary Gland Clear Evidence Clear Evidence ADENOMA 0/44 0/42 8/41 Neoplastic Lesions
Yes TR-340 5634-39-9 Iodinated glycerol Mice B6C3F1 Female Gavage Pituitary Gland Some Evidence Some Evidence ADENOMA 10/47 15/45 24/46 Neoplastic Lesions
Yes TR-388 96-45-7 Ethylene thiourea (ETU) Mice B6C3F1 Female Dosed-Feed Pituitary Gland Clear Evidence Clear Evidence ADENOMA 10/47 19/49 26/49; CARCINOMA 1/47 0/49 0/49 Neoplastic Lesions
Yes TR-595 CELLPRADCDMA Cell Phone Radiation: CDMA Rats Hsd:Sprague Dawley SD Male Whole Body Exposure Pituitary Gland Clear Evidence Equivocal Evidence pars distalis, adenoma (17/89, 25/90, 34/90, 13/90) May Have Been Related
Yes TR-589 32534-81-9 Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] Rats Wistar Han Male Gavage Pituitary Gland Clear Evidence Clear Evidence (pars distalis): adenoma 19/49 12/49 22/50 35/50 Neoplastic Lesions
Yes TR-545 446-72-0 Endocrine disruptor (Genistein) Rats Sprague Dawley Female Dosed-Feed Pituitary Gland Some Evidence Some Evidence ADENOMA OR CARCINOMA 38/54 32/49 40/50 44/50 Neoplastic Lesions
Yes TR-545 446-72-0 Endocrine disruptor (Genistein) Rats Sprague Dawley Female Dosed-Feed Pituitary Gland Some Evidence Some Evidence ADENOMA OR CARCINOMA 38/54 40/50 34/50 46/49 Neoplastic Lesions
Yes TR-595 CELLPRADGSM Cell Phone Radiation: GSM Rats Hsd:Sprague Dawley SD Male Whole Body Exposure Pituitary Gland Clear Evidence Equivocal Evidence pars distalis, adenoma (17/89, 28/90, 26/90, 26/90) May Have Been Related